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Background: Genitourinary embryonal rhabdomyosarcoma is rarely reported in China. This retrospective analysis
aimed to characterize the clinicopathologic features and treatment outcomes of genitourinary embryonal
rhabdomyosarcoma in a sample of Chinese patients.
Methods: Basic demographic and clinical data of 29 patients, who were diagnosed with genitourinary embryonal
rhabdomyosarcoma between January 2000 and December 2011, were retrieved and analyzed.
Results: In these patients, 25 were males and 4 were females with a median age of 12 years. Paratesticule was the
most common lesion site, followed by the prostate, bladder, and vagina. The median tumor size was 5.80 cm. Six
patients had clinically positive regional nodes. At the initial diagnosis, patients had a metastatic disease. According
to the TNM staging classification for the IRS-IV, phase I lesions were detected in ten cases, phase II lesions in six
cases, phase III lesions in four cases, and phase IV lesions in nine cases. The median survival of all patients was 63
(range from 6 to 118) months. The 1-, 3-, and 5-year survival rates for these patients were 93%, 83%, and 52%,
respectively. Multivariate analyses demonstrated that staging and anemia were significant predictors of prognosis.
Conclusions: Our findings suggest that metastasis predicts a poor prognosis. Chemotherapy played an important
role in comprehensive treatment. Palliative and neo-adjuvant chemotherapy could increase median survival time.
Keywords: Genitourinary embryonal rhabdomyosarcoma, Chinese patients, Treatment, ChemotherapyBackground
Rhabdomyosarcoma is a rare disease, accounting for 3% of all
childhood cancers. A total of 350 new cases occur each year es-
timated in the USA [1]. Rhabdomyosarcoma can develop in al-
most any part of the body, and in up to 29% of the cases, it
arises in genitourinary organs [2], including the bladder, pros-
tate, vagina, and paratesticule. Alveolar and embryonal rhabdo-
myosarcomas are the two most common histological subtypes
of rhabdomyosarcoma. Approximately, 90% of genitourinary* Correspondence: xiaokzhang9@163.com
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creativecommons.org/publicdomain/zero/1.0/rhabdomyosarcoma cases in non-Chinese patients are embry-
onal [3]. Little is known about genitourinary embryonal rhabdo-
myosarcoma in the Chinese population. This retrospective
study attempted to characterize the clinicopathological manifes-
tations and evaluate the current treatment outcomes of genito-
urinary embryonal rhabdomyosarcoma in China.Methods
Patients and ethnic consideration
Medical records of patients, who were diagnosed with
embryonal rhabdomyosarcoma and treated at Friendship
Hospital in Beijing between January 2000 and December
2011, were reviewed. After exclusion of retroperitoneal
and pelvic embryonal rhabdomyosarcomas, 29 cases of
genitourinary embryonal rhabdomyosarcoma included inicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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clinical and histopathological features, and treatment
outcomes were analyzed.
The study was approved by Beijing Friendship Hospital
Ethics Committee and conducted in compliance with
the provisions of the Declaration of Helsinki. Informed
written consent was obtained from all subjects.
Diagnosis of genitourinary embryonal
rhabdomyosarcoma
The diagnosis was made based on the results of physical
examination and various tests (e.g., blood biochemistry
test, computed tomography (CT) of the abdomen and
pelvis, chest radiography, magnetic resonance imaging
(MRI) and bone scanning in all cases, and bone marrow
aspiration in some cases). Fine needle biopsy was per-
formed on all patients, and radical surgery was per-
formed in 20 cases. Lymph node involvement was
determined by biopsies, surgical specimens, and/or CT
scanning.
Histology and immunohistochemical staining
Immunohistochemical staining was performed to detect
desmin- and myogenin-positive cells in all 29 resected
tumor tissue specimens. Pathological assessment was
performed by two experienced pathologists independ-
ently, and findings including histological tumor type,
depth of invasion, size, margins, and lymphatic invasion
were recorded.
Treatment and follow-up
The lesion was staged according to the American Joint
Committee on Cancer (AJCC) staging system [4]. Of the
29 patients, 27 received chemotherapy. Responses were
assessed by computed tomography or magnetic reson-
ance imaging scans based on the standard response
criteria referred to as Response Evaluation Criteria in
Solid Tumors (RECIST) [5]. Time-to-tumor progression
(TTP) is defined as the period between treatment initi-
ation and objective tumor progression, progression-free
survival (PFS) is defined as the time from randomization
until objective tumor progression or death, and overall
survival is defined as the time from diagnosis to the
death or last visit were recorded.
Patients were followed up to 30 December 2012 by
telephone or mail. At each follow-up, complete informa-
tion on vital status was censored. No single patient was
lost to follow-up.
Statistical analysis
Survival data were analyzed using the Kaplan-Meier
method and the log-rank test. Differences were considered
statistically significant when P < 0.05. The software SPSS
15.0 (Chicago, IL, USA) was used.Results
Clinicopathological characteristics
A total of 129 patients were diagnosed with embryonal
rhabdomyosarcoma, among whom 29 (22.48%) had
genitourinary embryonal rhabdomyosarcoma. The basic
demographic and clinicopathologic data of these 29 pa-
tients are presented in Table 1. Briefly, genitourinary
embryonal rhabdomyosarcoma occurred predominantly
in males; the primary lesion sites were paratesticule, the
prostate, and bladder in male patients but exclusively in
the vagina in female patients; genitourinary embryonal
rhabdomyosarcoma occurred at a much younger age in
female patients than in male patients.
Survival data
At the time of the last follow-up, 5 patients were still
alive. The overall median, 1-, 3-, and 5-year survival
rates of the 29 patients were 63 (range from 6 to 118),
93%, 83%, and 52%, respectively (Figure 1). The survival
was not associated with sex, age, and primary sites.
Moreover, the survival time of patients with anemia was
shorter than those patients without anemia. The detailed
data was shown in Table 2.
Prognostic significance of staging and anemia
Given that staging was based on tumor size and
regional node involvement, multiple regression ana-
lysis was not appropriate to assess tumor size and
lymph node involvement as an independent variable;
thus, a multivariate analysis was performed. This ana-
lysis showed that staging and anemia were independ-
ent prognostic factors for genitourinary embryonal
rhabdomyosarcoma (Table 3).
Treatment
In the 29 patients, 24 received at least one form of treat-
ment, 3 only received a single treatment and 2 declined
treatment. Surgery was performed in 22 cases, radiother-
apy in 14 cases, and chemotherapy in 27 cases (Table 4).
Tumor sites
Paratesticule
Embryonal rhabdomyosarcoma was diagnosed in the
paratesticule where painless scrotal mass was presented
in 10 patients. They were all younger than 10 years (me-
dian age of 15 years and range 12 to 26 years). Before
surgery, CT scanning was performed on all patients, and
the histological type was determined by immunohistolo-
gical staining. At diagnosis, 7 of these patients had a
local disease, and the other 3 had a metastatic disease
(anemia in one case). The median diameter of tumor
was 4.9 cm (range 4.0 to 13 cm), and for an unknown
reason, the tumor was biggest in diameter in one anemia
case.
Table 1 Characteristic of patients according to the primary sites
All patients Paratesticular Prostate Bladder Vagina
N = 29 N = 10 N = 8 N = 7 N = 4
Sex
Male 25 10 8 7 -
Female 4 - - - 4
Median age, years (range) 12 (2 to 27) 15 (12 to 26) 9 (3 to 27) 6.5 (2 to 19) 3.5 (2 to 20)
Number of patients <10 14 - 5 6 3
>10 15 10 3 1 1
Number of patients <2 16 5 3 5 3
>2 14 5 5 2 1
Status at diagnosis
Number of patients Organ confined 20 7 4 6 3
Metastatic 9 3 4 1 1
WBC 6.8
RBC 392 391.5 355 403 444.5
Hb 130 129 126.5 137 137
Anemia 5 1 2 1 1
Plt 197 182 173 223 212
Median tumor size (cm) 5.6 (2.5 to 15) 4.9 (4.0 to 13) 7.0 (3.0 to 15) 6.0 (4.5 to 8.7) 3.0 (2.5 to 5.8)
Number of patients <5 11 6 2 1 3
>5 18 4 6 6 1
Regional nodes
Number of patients Negative 23 9 7 4 3
Positive 6 1 1 3 1
IRS staging
Number of patients I 10 7 - - 3
II 6 - 3 3 -
III 4 - 1 3 -
IV 9 3 4 1 1
WBC, white blood cells; RBC, red blood cells; Hb, hemoglobin; IRS, Intergroup Rhabdomyosarcoma Study; Plt, platelet.
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cluding retroperitoneal lymph node dissection (RPLND)
and adjuvant chemotherapy (VAC regimen (vincristine,
actinomycin D, and cyclophosphamide) or IVA regimen
(ifosfamide, vincristine, and actinomycin D)) for 10 to 12
months. The median disease-free survival (DFS) was 29
months. Four (80%) patients developed metastatic disease
after adjuvant chemotherapy and were treated with multi-
drug chemotherapy. Two (20%) patients received neo-
adjuvant chemotherapy (VAC for 8 weeks) followed by
salvage surgery, and both had partial response and achieved
complete tumor resection (R0) with a consolidation chemo-
therapy for 3 months. Two patients developed recurrent
disease and metastatic disease during follow-up period and
received salvage chemotherapy. The 2 patients with
metastatic disease at the time of diagnosis and 6
patients who developed metastatic disease receivedpalliative chemotherapy. The agents included vincrine,
dactinomycin, ifosfamide, etoposide, cyclophosphamide,
epirubicin, adriamycin, cisplatin, carboplatin, irinote-
can, gemcitabine, and bevacizumab. VAC and IVA were
administrated as the first-line chemotherapy. Patients
who underwent chemotherapy as the first-line treatment
had a response rate (RR) of 20%, and those with relapse
had an RR of 80%. The median TTP was 9.5 months, and
median survival time was 29 months. One patient who was
treated with irinotecan and bevacizumab achieved partial
remission. The DFS was 8 months. One patient refused
chemotherapy and died of pneumocystis pneumonia 10
months after diagnosis.
Survival: Patients were followed up for a median of 96
months. Three of them were alive at the end of follow-up.
The 1-, 3-, and 5-year survival rates were 90%, 80%, and
70%, respectively. Median overall survival was 82 months.
Figure 1 The survival curve of 29 patients diagnosed with embryonal rhabdomyosarcoma.
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The median age of the 4 female patients was 3.5 years,
and only 1 patient was older than 10 years who pre-
sented with irregular menstruation. Before surgery, all
had CT scanning. The histological type of the lesion was
confirmed by experts. At diagnosis, 3 patients had a
local disease and 1 patient had a metastatic disease
(anemia in one case). The median diameter of tumors
was 3.0 cm (range 2.5 to 5.8 cm). Only one patient had
clinically positive regional nodes.Treatment
Two patients received radical surgery, followed by ad-
juvant chemotherapy (VAC for 12 months). The DFS
was 35 and 39 months, respectively, in these two pa-
tients. All patients developed a metastatic disease after
adjuvant chemotherapy. One of them underwent neo-
adjuvant chemotherapy with VAC for 6 weeks. After a
partial response, this patient moved onto salvage sur-
gery and radiotherapy with 45 Gy and achieved a DFS
of 39 months. One patient was initially diagnosed with
a metastatic disease, and two patients developed a
metastatic disease. These three patients underwent
chemotherapy with multiple drugs including vincrine,
ifosfamide, etoposide, teniposide, cyclophosphamide,
epirubicin, adriamycin, cisplatin, carboplatin, irinote-
can, and gemcitabine. Patients undergoing this first-
line multidrug chemotherapy had an RR of 33%, and
those with relapse had an RR of 67%. The median sur-
vival time of these patients was 38 months.Survival
These patients were followed up for a median of 96
months. At the end of follow-up, only one patient was
alive. The 1-, 3-, and 5-year survival rates were 100%,
50% and 50%, respectively. The median overall survival
was 96 months.Prostate
Rhabdomyosarcoma was detected in the prostate in 8
patients with a median age of 9 (range 3 to 27) years.
The embryonal type of the lesion was confirmed by pa-
thologists. Of these patients, 3 were over 10 years old
and presented with gross hematuria, 4 had a local dis-
ease, 4 had a metastatic disease, and 2 had anemia. The
median diameter of tumor was 7.0 cm (range 3.0 to 15
cm), and only 1 patient had clinically positive regional
nodes. Based on the TNM staging classification for the
IRS-IV, phase II lesion was in three cases, phase III le-
sion in one case, and phase IV lesion in four cases.Treatment
Three (37.5%) patients received radical surgery and adju-
vant chemotherapy (VAC or IVA for 8 to 10 months) and
achieved a median DFS of 17 months. One patient had re-
gional node involvement and underwent neo-adjuvant
chemotherapy and salvage surgery. Three patients pre-
sented with a metastatic disease at diagnosis, and 3 patients
advanced to a metastasis disease. These 6 patients all re-
ceived multidrug first-line chemotherapy with vincrine,
vinorelbine, ifosfamide, etoposide, cyclophosphamide,










Sex Male 92 88 52 63
Female 100 50 50 96 0.479
Age
≤10 100 93 53 63
>10 86 64 50 66 0.899
Anemia No 100 96 63 67.33
Yes 60 20 0 25 <0.001
Tumor size
≤5 100 91 91 88.5
>5 89 78 28 52 <0.001
Regional nodes
Negative 96 87 61 67
Positive 83 67 17 54 0.033
Status
Local 100 95 75 76
Metastatic 78 56 0 39 <0.001
Primary sites
Paratesticular 90 80 70 82
Prostate 88 88 38 52
Bladder 100 100 43 61
Vagina 100 50 50 96 0.349
Sites Non-B/P 93 71 64 82
B/P 93 87 40 59 0.084
Staging
I 100 90 90 88
II 100 100 83 67
III 100 100 25 58
IV 78 56 0 39 <0.001
B/P, bladder or prostate; OS, overall survival.
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can, and gemcitabine and had an RR of 33%, and those
with relapses had an RR of 67%. The median survival
was 26.5 months. In the very 1 patient with anemia,
bone marrow involvement was revealed by bone mar-
row smears. One patient had a large tumor (10.5 cm
in diameter) with metastasis in multiple regionalTable 3 The staging and anemia confirmed result
B SE Wald df
Lower Upper Lower Uppe
Status at diagnosis .983 1.075 .837 1
Staging AJCC .993 .358 7.704 1
Anemia −2.596 1.119 5.380 1
AJCC, American Joint Committee on Cancer; CI, confidence interval.lymph nodes. Despite multiple cycles of chemother-
apy, no lesion shrinking was observed and the patient
only lived disease-free for 2.5 months that was in a
sharp contrast a median overall survival of 22 months
in the 8 patients in this category. One patient who did
not receive any treatment died 8 months after
diagnosis.Significance Exp (B) 95.0% CI for Exp (B)
r Lower Upper Lower Upper
.360 2.672 .983 1.075
.006 2.699 .993 .358
.020 .075 −2.596 1.119
Table 4 Performed treatment in 29 patients
Number of
patients
All Paratesticular Prostast Bladder Vagina
29 10 8 7 4
Surgery 20 7 4 6 3
Radiotherapy 6 0 1 4 1
Chemotherapy 27 9 7 7 4
Single modality 7 2 3 1 1
Combined modality 20 7 4 6 3
No treatment 2 1 1 0 0
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The patients were followed up for a median of 48
months, and no one was alive by 30 December 2011.
The 1-, 3-, and 5-year survival rates were 88%, 88%,
and 38%, respectively. Median overall survival was 52
months.Bladders
Even patients had lesions in the bladder which were con-
firmed by experienced pathologists as an embryonal
type. They were all younger than 10 years (median age
of 6.5 years) except that 1 patient was 19 years old who
presented with gross hematuria and frequent urination.
Before surgery, all these patients underwent CT scan-
ning. Initially, 6 patients were diagnosed with a local dis-
ease and 1 with a metastatic disease complicated by
anemia. The median diameter of tumor was 6.0 (range
4.5 to 8.7) cm, and 3 patients had clinically positive re-
gional nodes. Based on the TNM staging classification
for the IRS-IV, phases II and III lesions were each in
three cases and phase IV lesion was in the other case.Treatment
Three of the seven patients received radical surgery,
followed by adjuvant chemotherapy (either VAC or IVA
for 10 to 12 months) and radiotherapy. The median DFS
was 18 months. Two of these three patients developed
metastatic disease. Three patients with regional node in-
volvement underwent neo-adjuvant chemotherapy (50 to
60 Gy every 5 to 6 weeks), followed by salvage surgery
and radiotherapy. The DFS was 22 months. The very 1
patient with metastatic disease at initial diagnosis to-
gether with the 3 patients who developed metastasis dis-
ease accepted palliative chemotherapy with a regimen
including bleomycin, vincrine, ifosfamide, cyclophospha-
mide, epirubicin, adriamycin, cisplatin, carboplatin, iri-
notecan, and gemcitabine. Patients who received the
IVA regimen-based chemotherapy had an RR of 25%
while those with relapses had an RR of 75%. The median
survival was 27 months.Survival
The 7 patients were followed up for a median of 64
months. By 30 December 2011, only 1 patient was alive.
The 1-, 3-, and 5-year survival rates were 100%, 100%,
and 43%, respectively. Median overall survival was 61
months.
Discussion
Genitourinary embryonal rhabdomyosarcoma is com-
mon in children and young adults. In general, the inci-
dence of this disease is significantly higher in males than
in females [6]. The common sites of the lesions include
the bladder, prostate, paratesticule, and vagina. Regional
lymph node involvement is frequently found in parates-
ticular rhabdomyosarcoma. Most often, tumor growth
results in genitourinary obstruction. Most frequently,
genitourinary embryonal rhabdomyosarcoma invades the
lung, serosal surface, distant nodes, and bone [4]. In this
study, the median age of the subjects was 12 years. The
most common lesion site was the paratesticule, followed
by the prostate, bladder, and vagina; the median tumor
size was 5.60 cm in diameter, and the tumor in the pros-
tate was largest with a median diameter of 7.0 cm;
lymph node involvement most frequently occurred in
bladder lymph nodes; metastasis occurred most fre-
quently in soft tissue, followed by the lung and bone;
subjects in this cohort had a significantly lower survival
rate and a significantly higher proportion of metastatic
disease as compared with subjects in previous studies
[5]. It has to be pointed out, however, 2 patients did not
receive any active treatment, and some patients only re-
ceived chemotherapy or radiotherapy. These might have
a negative effect on the survival rate.
Radical surgery used to be the solely primary treat-
ment for genitourinary embryonal rhabdomyosarcoma
[3]. However, this approach is associated with a low sur-
vival rate (about 20%) [7]. Moreover, the procedure in-
volves a wide extent of resection, often resulting in
normal tissue damage and organ (especially urogenital
tract) dysfunction [8]. Radiation therapy is another treat-
ment option for genitourinary embryonal rhabdomyosar-
coma; it may achieve a local control of tumor growth in
Zhan et al. World Journal of Surgical Oncology  (2015) 13:190 Page 7 of 10patients who have undergone an initial surgical resection
but fails to improve patient survival substantially. Com-
piling clinical data have come to realize that rhabdomyo-
sarcoma is a microscopic metastatic disease that is
highly sensitive to chemotherapy [9,10]. Numerous
studies have demonstrated that chemotherapy may pro-
long the disease-free survival of patients with localized
rhabdomyosarcoma by approximately 70% [11]. At
present, adjuvant chemotherapy has become a routine in
the management of rhabdomyosarcoma. Two regimens
have been recommended. While the VAC regimen is
widely used worldwide, the IVA regimen is predomin-
antly adopted in European countries.
Despite various treatment regimens, complete resec-
tion cannot be always attainable, particularly pelvic
tumor cases. In patients with unresectable lesions, initial
chemotherapy has a high response rate [12]. Neverthe-
less, surgery should be considered whenever possible
after the initial chemotherapy since multiple studies have
previously showed complete resection with negative
margins after preoperative chemotherapy. Moreover, it
has been documented that addition of neo-adjuvant
chemotherapy may help preserve normal anatomy, im-
prove bladder function, and increase the overall survival
in genitourinary rhabdomyosarcoma patients [13,14]. In
our study, almost all patients received adjuvant chemo-
therapy, a partial response (PR) was achieved in 5 pa-
tients who received neo-adjuvant chemotherapy, and the
overall response rate was 100%. In all cases, the lesions
became a surgically resectable disease, and complete ex-
cision was achieved. Nevertheless, the efficacy, toxicity
and optimal dose, and time of neo-adjuvant chemother-
apy warrant further more large-scale studies.
Clinical outcomes of the patients who were initially di-
agnosed with a metastasis disease were poor in this
study. During the last 30 years, introduction of chemother-
apy and radiation into the treatment of nonmetastatic
rhabdomyosarcoma has improved the 3-year survival to
86% [15], which is in a sharp contrast to 30% for patients
with a metastatic disease [16]. Treatment of metastatic
rhabdomyosarcoma remains a significant challenge to on-
cologists. Although high-dose chemotherapy with stem cell
rescue in a series of studies has achieved a high objective
response rate, the ultimate outcome of patients with meta-
static rhabdomyosarcoma remains unsatisfactory [17,18].
Therefore, considerable research and clinical efforts have
been devoted to the development of new therapeutic strat-
egies for metastatic rhabdomyosarcoma, and novel agents
have showed potential anticancer activities in clinical trials.
Irinotecan, a topoisomerase I inhibitor, has shown thera-
peutic potential for patients with rhabdomyosarcoma after
failure with multidrug chemotherapy in preclinical studies
and phase I trials [19,20]. In a further phase II trial, when
irinotecan was used alone, it achieved a response rate of11.4% in patients with recurrent or refractory rhabdomyo-
sarcoma with a median time to progression of 1.4 years
[21]. For newly diagnosed metastatic rhabdomyosarcoma,
the response rate to irinotecan reached 42% to 45%. When
vincristine and irinotecan were combined for relapsed
rhabdomyosarcoma, the best overall objective response rate
was 31.5%, and the median survival time was 1.4 years.
When vincristine and irinotecan were used for newly diag-
nosed metastatic rhabdomyosarcoma, the response rate
was 70%, and the survival rate could reach 71% [21]. Irino-
tecan is highly active against metastatic rhabdomyosarcoma
and has attracted further investigations. Gee et al. have re-
ported that vascular endothelial growth factor (VEGF) re-
ceptors exist in embryonal rhabdomyosarcoma where
VEGF binding to VEGR receptors eventually promotes
tumor cell proliferation [22]. Based on a previous retro-
spective study, rhabdomyosarcoma patients with high
circulating levels of VEGF have poor survival [23]. In xeno-
graft models of rhabdomyosarcoma, bevacizumab, an anti-
VEGF mAb, has been demonstrated to be capable of inhi-
biting tumor growth and metastases and enhancing tumor
sensitivity to radiation [24,25], thus possessing a therapeutic
potential for refractory rhabdomyosarcoma. Ola Lindén re-
ported an embryonal rhabdomyosarcoma case where the
chemorefractory disease became resectable after radiother-
apy in addition to treatment with bevacizumab and statins,
and no progression occurred following postoperative adju-
vant chemotherapy plus bevacizumab for 7 cycles [26]. In
another study, compassionate use of bevacizumab in con-
comitance with topotecan on refractory or recurrent
rhabdomyosarcoma resulted in a partial remission [27]. As
demonstrated in a phase I study, bevacizumab is well-
tolerated in children [28]. Currently, a phase II study is on-
going to evaluate the efficacy and safety of bevacizumab
combined with chemotherapy for childhood and adolescent
metastatic rhabdomyosarcoma.
A better understanding of molecular pathways in-
volved in cancer development would identify potential
therapeutic targets. Cumulating evidence has showed
that insulin-like growth factor (IGF) signaling plays an
important role in survival of patients with embryonal
rhabdomyosarcoma [29,30], and thus, humanized mono-
clonal antibodies and small kinase inhibitors have been
evaluated in many preclinical studies [31,32]. At present,
a study sponsored by COG is underway to evaluate
IMC-A12 and a monoclonal anti-IGF-IR antibody as a
combination therapy for metastatic rhabdomyosarcoma.
Moreover, it has been shown that epidermal growth fac-
tor receptor (EGFR) is highly expressed in embryonal
rhabdomyosarcoma cells and thus may serve as a candi-
date therapeutic target [33]. Several studies, indeed, have
shown that anti-EGFR-mediated neutralization of EGFR
may result in effective growth inhibition of embryonal
rhabdomyosarcoma cell lines in vitro [34,35]. It is highly
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a novel therapeutic for embryonal rhabdomyosarcoma.
In our study, the very 1 patient who presented with a
progressive disease failed to respond to either a two-
chemotherapy regimen or radiotherapy but achieved an
exciting outcome after treatment with topotecan and
bevacizumab in combination; the tumor size was re-
duced over 30%, and during the 11-month follow-up, no
evident relapse was observed. It appears that bevacizu-
mab is helpful in the management of relapsed chemore-
fractory rhabdomyosarcoma.
There are two staging systems for rhabdomyosarcoma.
The Intergroup Rhabdomyosarcoma Study (IRS) has
been using the clinical grouping (CG) system since 1972.
This system stages rhabdomyosarcoma based on the
extent of resection but does not include important prog-
nostic factors, such as tumor size and lymph node
involvement [36]. The other system is tumor-node-
metastasis (TNM) staging system which classifies the
cancer by its primary site, tumor size, regional node in-
volvement, and the presence or absence of distant me-
tastasis. Now, the TNM system is widely accepted
worldwide [37]. In this system, tumor site is viewed as a
prognostic factor. Unfavorable anatomic sites of the gen-
itourinary system are the prostate and the bladder
whereas favorable anatomic sites include the paratesti-
cule and the vagina [38]. Results from the International
Society of Pediatric Oncology (SIOP) and the IRS group
showed that non-bladder/prostate genitourinary rhabdo-
myosarcoma has a better 5-year survival than bladder/
prostate rhabdomyosarcoma [39]. In our study, the over-
all survival of bladder/prostate rhabdomyosarcoma was
worse than that of non-bladder/prostate cases. However,
the difference did not reach a statistically significant
level, probably due to the limited number of patients.
Several previous studies have demonstrated that age is
a prognostic factor for patients with rhabdomyosarcoma.
A study analyzing IRSG data showed that children aged
between 1 and 10 years had a better survival rate com-
pared to those older than 10 years [40]. A retrospective
analysis of 2,600 rhabdomyosarcoma cases showed that
adults had a worse outcome than children, and the 5-
year overall survival was 27% for adults but 61% for chil-
dren [41]. Rhabdomyosarcoma appears to occur in un-
favorable sites more frequently in adults. However,
another retrospective study involving cases from a single
institution indicated that the survival rate in adult
rhabdomyosarcoma patients was not significantly lower
than that in children with rhabdomyosarcoma if similar
treatments were applied [42]. In addition, a report from
the IRS-IV suggested that age did not affect survival in
patients with a metastatic disease [16]. In our study, for
the same pathological subtype, the survival rate was not
significantly different between children aged under 10years and those aged over 10 years. Moreover, the out-
come in younger patients was worse than that in older
patients. Thus, pathological types and therapeutic effects
should be taken into consideration in further studies.
It has to be pointed out that patients with anemia had
a shorter survival; the median survival was only 9
months and 1 year-survival rate was close to 0. Among
the patients analyzed, 3 presented with chronic bleeding
and 1 with bone marrow involvement. According to the
current literature, bone marrow metastasis is not uncom-
mon, and the incidence of bone marrow involvement at
diagnosis varies from 29% to 50% [43]. Early diagnosis of
bone marrow involvement is difficult because of the lack of
specific clinical manifestations. Abnormal changes in
complete blood count such as anemia, neutropenia or
leukocytosis, and thrombocytopenia occur in some patients
with bone marrow involvement [44]. According to a report
from the IRS, although patients with bone marrow metasta-
sis have a high response rate to the VAC regimen, the best
survival time is seldom beyond 4 years [45]. In our study, 1
patient with advanced prostate embryonal rhabdomyosar-
coma with hemoglobin (Hb) 65 g/L was diagnosed with
bone marrow metastasis. Abdomen CT and MRI findings
showed enlarged retroperitoneal lymph nodes and a pri-
mary mass of 8.5 cm in diameter protruding into the infer-
ior part of the bladder. This patient underwent 8 cycles of
chemotherapy with three different protocols but showed no
response even to vincristine plus irinotecan. The median
TTP was 3 months, and the overall survival time was 21
months. Patients with anemia at diagnosis were associated
with large tumor mass, concomitant metastasis to lymph
nodes and lungs and thus had poor prognosis.
The incidence of genitourinary embryonal rhabdomyo-
sarcoma is quite low in China, the current study is a
single-center retrospective study with maximum Chinese
cases so far based on my knowledge, so I think this will
bring a valuable knowledge to this field. Compared to
the documents from other countries, Chinese patients in
our institute received a similar treatment with the same
guideline but have the lower survival rate compared to
western countries. We preliminarily guess that is be-
cause of race difference but needs further detailed
research.
This study has several limitations. First, this was a
retrospective study with a small sample size. Second, the
patients analyzed were treated by different surgeons.
Without a standardized protocol, a surgeon’s experience
might affect patient outcome. Third, in the analyzed
cases, VAC was used as the neo-adjuvant chemotherapy
regimen. However, there were no unified guidelines on
neo-adjuvant treatment, and thus, the treatment dose
and duration and the number of treatment cycles were
not optimized. Fourth, the data on drug toxicities were
incomplete. Despite these limitations, this study for the
Zhan et al. World Journal of Surgical Oncology  (2015) 13:190 Page 9 of 10first time have characterized the clinicopathologic fea-
tures and evaluated the treatment outcomes of genito-
urinary embryonal rhabdomyosarcoma in a sample of
Chinese patients.
Conclusions
Multimodality treatment including surgical operation,
chemotherapy, and radiotherapy has gradually become
the primary treatment for genitourinary embryonal
rhabdomyosarcoma. For unresectable disease, neo-
adjuvant chemotherapy plays an important role in maxi-
mizing the preservation of a functional bladder, increas-
ing resection rates and improving the quality of life.
However, metastatic disease with unfavorable prognosis
has limited treatment choices and warrants development
of novel therapeutic approaches. The findings in this
study also support that the prognosis of genitourinary
embryonal rhabdomyosarcoma is not necessarily poorer
in older than in younger patients.
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